| P50 | author | Diethelm Wallwiener | Q1223199 |
| | Florin-Andrei Taran | Q38291137 |
| | Markus Wallwiener | Q41603467 |
| P2093 | author name string | Tanja Fehm | |
| | Markus Wallwiener | |
| | Andreas Daniel Hartkopf | |
| | Florin Andrei Taran | |
| | Ines Gruber | |
| | Juergen Hoffmann | |
| | Markus Hahn | |
| | Natalia Krawzyck | |
| P2860 | cites work | HER-2 gene amplification can be acquired as breast cancer progresses | Q24563115 |
| | Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 |
| | Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 |
| | Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study | Q34520174 |
| | A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer | Q34563755 |
| | The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients | Q35558100 |
| | Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up | Q35978377 |
| | A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation | Q36549817 |
| | ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients | Q37038635 |
| | Detection, clinical relevance and specific biological properties of disseminating tumour cells | Q37135356 |
| | Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up | Q37321938 |
| | HER2-positive DTCs/CTCs in breast cancer | Q38004902 |
| | Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients | Q39676823 |
| | Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial | Q39712731 |
| | Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients | Q40247816 |
| | Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells | Q40830360 |
| | The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse | Q44503403 |
| | A pooled analysis of bone marrow micrometastasis in breast cancer | Q44594123 |
| | Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial | Q48850027 |
| | Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. | Q51557042 |
| | Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. | Q52032203 |
| | Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. | Q54526390 |
| | Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. | Q54577990 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 353-360 | |
| P577 | publication date | 2014-02-20 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer | |
| P478 | volume | 144 | |